管腔型乳腺癌研究进展

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (4): 465-469.

管腔型乳腺癌研究进展

蒋艳¹, 张帆²

¹皖南医学院临床医学系,芜湖 241001,安徽;
²皖南医学院弋矶山医院病理科,芜湖 241001,安徽

收稿日期:2013-12-13 修回日期:2014-03-31 出版日期:2014-04-26 发布日期:2020-07-24
通讯作者: 张帆,通信作者,男,硕士生导师、副教授,研究方向:妇科及乳腺肿瘤病理学。Tel:0553-5739792 E-mail:zhangfan401401@aliyun.com
作者简介:蒋艳,女,硕士研究生,医师,研究方向:乳腺肿瘤病理学。Tel:0553-3996177 E-mail:117504434@qq.com

Advances in luminal breast cancer

JIANG Yan¹, ZHANG Fan²

¹Department of Clinical Medicine, Wannan Medical College, Wuhu 241001, Anhui, China;
²Department of Pathology, Yijishan Hospital of Wannan Medical Gollege, Wuhu 241001, Anhui, China

Received:2013-12-13 Revised:2014-03-31 Online:2014-04-26 Published:2020-07-24

摘要/Abstract

摘要： 利用免疫组化技术对乳腺癌从基因水平上加以分型,不仅能够判断肿瘤的预后,还能够预测肿瘤对治疗的反应,为肿瘤的个体化治疗提供依据。本文以管腔型乳腺癌为研究方向,从六个方面进行论述:管腔型乳腺癌的认识过程;管腔型乳腺癌的形态特征;管腔型乳腺癌的免疫表型;管腔型乳腺癌的基因表达;管腔型乳腺癌的分子遗传学;管腔型乳腺癌的临床特点及预后,为管腔型乳腺癌的进一步研究提供依据。

关键词: 乳腺癌, 管腔型, 免疫组化, Her-2

Abstract: We use the immunohistochemical techniques to be parting from breast cancer at the genetic level, not only to determine the prognosis of the tumor, but also be able to predict tumor response to treatment, provide the basis for individualized treatment of cancer. In this study, the research direction of luminal breast cancer, from six aspects discussed: the process of luminal breast cancer awareness; molecular luminal breast cancer; morphological features of luminal breast cancer; luminal breast cancer immune phenotype; gene expression of luminal breast cancer genetics; clinical features and prognosis of luminal breast cancer, providing a basis for further study of luminal breast cancer.

Key words: breast cancer, luminal like, immunohistochemical, human epidermal growth factor receptor 2

中图分类号:

R737

蒋艳, 张帆. 管腔型乳腺癌研究进展[J]. 中国临床药理学与治疗学, 2014, 19(4): 465-469.

JIANG Yan, ZHANG Fan. Advances in luminal breast cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(4): 465-469.

参考文献

[1] Jemal A,Siegel R,Xu J,et al.Caner statistics,2010[J]. CA Cancer J Clin, 2010,60(5):277-300.
[2] Simpson PT,Reis-Filho JS,Lakhani SR. Breast pathology:beyond morphology[J]. Semin Diagn Pathol, 2010,27(1):91-96.
[3] Perou CM, Sorlie T, Eisen MB,et al. Molecular portraits of human braest tumours[J]. Nature, 2000,406(6797):747-752.
[4] Yu K,Lee CH,Tan PH,et al.Conservation of breast cancer molecular subtypes and transcriptional patterns of tum or progression across distinct ethic population[J]. Clinical Cancer Research, 2004, 10 (16):5508-5517.
[5] Sorlie T,Tibshirani R,Parker J,et al. Repeated observation of breast umor subtypes in independent gene expression data sets [J].Proc Natl Acad Sci USA, 2003,100(14):8418-8423.
[6] Goldhirsch A,Wood WC,Coates AS,et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Ann Oncol, 2011,22(8):1736-1747.
[7] Lakhani SR,Ellis IO,Schnitt SJ,et al.WHO classification of tumours of the breast[M]. Lyon:IRAC Press, 2012.
[8] Frierson HJ Jr, Wolber RA,Berean KW,et al.Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma[J].Am J Clin Pathol, 1995,103(2):195-198.
[9] Geyer FC,Rodrigues DN,Weigeit B,et al,Molecular classification of estrogen receptor/luminal breast cancers[J].AdvAnat Pathol, 2012,19(1):39-53.
[10] Carlson RW,Allred DC,Anderson BO,et,al,Invasive breast cancer[J].J Natl Compr Canc Netw, 2011,9(2):136-222.
[11] Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J].Arch Pathol Lab Med, 2010,134(6):907-922.
[12] Howard EM,Lau SK,Lyles RH,et al.Correlation and expression of p53, HER-2,vascular endothelial growth factor(VEGF),and E-cadherin in a high-risk breast cancer population[J].Int J Clin Oncol, 2004,9(3):154.
[13] 《乳腺癌HER-2检测指南(2009版)》编写组.乳腺癌HER-2检测指南(2009版)[J].中华病理学杂志,2009,38:836-840.
[14] Ross JS.Human epidermal growth factor receptoo 2 testing in 2010:does chromosome 17 centromere copr number make any difference[J]. J Clin Oncol, 2010,28(28):4293-4295.
[15] Tse CH,Hwang HC,Goldstein LC,et,al.Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes:implications for anti-HER2 targeted therapy[J]. J Clin Oncol, 2011, 29(31):4168-4174.
[16] Nishimura R, Osako T, Okumura Y,et al.Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer[J]. Exp Therap Med, 2010,1(5):747-754.
[17] Cheang MC,Chia SK,Voduc D,et al.Ki-67 index, HER-2 status,and prognosis of patients with luminal B breast cancer[J]. J Natl Cancer Inst, 2009,101(10):736-50.
[18] Kobayashi T, lwaya K, Moriya T, et al. A simple immunohistochemical panel comprising 2 conventional markers, Ki-67 and P53, is a powerful tool for predicting patient outcome in luminal-type breast cancer[J]. BMC Clin Pathol, 2013, 13:5.
[19] Whitfifld ML,Sherlock G,Saldanha AJ, et al.Identification of genes periodically expressed in the human cell cycle and their expression in tumors[J].Mol Biol Cell, 2002,13(6):1977-2000.
[20] Badve S,Turbin D,Thorat MA, et al.FOXA1 expression in breast cancer-correlation with luminal subtype Aand survival[J].Clin Cancer Res, 2007,13(15):4415-4421.
[21] 陈桂秋,卢一燕,王丽萍,等.乳腺癌分子分型研究进展[J].中国实验诊断学,2011,15(6):1130-1133.
[22] 水若鸿,杨文涛,龚西騟,等.腔面型乳腺癌的临床病理特征和研究进展[J]. 临床与实验病理学杂志,2013,29(3):235-239.
[23] Loi S,Haibe-Kains B, Majjaj S,et al.PIK3CA mutations associated with gene signature of low Mtorc1 signaling and better outcomes in estrogen receptor-positive breast cancer[J]. Proc Natl Acad Sci, 2010,107(22):10208-10213.
[24] Ellis MJ,Lin L,Crowder R,et al.Phosphatidy-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer[J]. Braest Cancer Res Treat, 2010,119(2):379-390.
[25] Brachmann S, Fritsch C,Maira SM,et al.PI3K and mTOR inhibitors:a new generation of targeted anticancer agents[J].Curr Opin Cell Biol, 2009,21(2):194-198.
[26] Karn T, Ruckhaberle E, Hanker L, et al. Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance[J].Breast Cancer Res Treat, 2011,130(2):409-420.
[27] Pettersson F, Yau C, Dobocan MC, et al. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer[J].Clin Cancer Res, 2011,17(9):2874-2884.
[28] Katchman BA, Ocal IT, Cunliffe HE, et al. Exprssion of quiescin sulfhydryl Oxidase1 is associated with a highly invasive phenotype and correlates with a poor prognosis in luminal B breast cancer[J].Breast Cancer Res, 2013,15(2):R28.
[29] Morrison MM, Hutchinson K, Williams MM,et al.ErbB3 downregulation enhances luminal brrest tumor response to antiestrogens[J].J Clin Invest,2013,123(10):4329-4343.
[30] 赵晶,付丽,乳腺癌的分子分型[J/CD].中华乳腺肿瘤杂志(电子版),2009,3(2):195.
[31] Van Calster B,Vanden Bempt I,Drijkoningen M,et al.Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2status:triple positive tumors are more likely lymph node positive[J].Breast Cancer Res Treat, 2009,113(1):181-187.
[32] Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer:classification, prognostication, and prediction[J]. Lancet, 2011, 378(9805):1812-1823.